Table 3.
tALP and PSA response rates
| Retreatment | |
|---|---|
| N = 44 | |
| tALP, n/Na (% response)b | |
| 12 weeks | 13/33 (39) |
| 24 weeks | 11/36 (31) |
| Any time before database cutoffc | 19/44 (43) |
| PSA, n/Na (% response)b | |
| 12 weeks | 2/32 (6) |
| 24 weeks | 0/36 (0) |
| Any time before database cutoffc | 4/44 (9) |
a
n/N = patients with response/patients with valid laboratory assessment.
b
tALP and PSA response defined as ≥30% decline from baseline. PSA response confirmed by a subsequent PSA value ≥4 weeks later.
c
N = safety population; patients with no valid postbaseline laboratory assessment were counted as nonresponders; database cutoff was June 11, 2015.
PSA, prostate-specific antigen; tALP, total alkaline phosphatase.